The Digital Therapeutics Market is projected to reach $22.16 billion by 2030, at a CAGR of 20.3% from 2023 to 2030. Digital therapeutics (DTx) delivers evidence-based therapeutic interventions to prevent, manage, or treat a range of patients' physical, mental, and behavioral conditions using high-quality software programs. Digital therapeutics consists of software and devices that support self-managing symptoms.
Clinicians recommend digital therapeutics due to improved patient outcomes and experience. Behavioral changes and self-management improve patients’ overall experience in care management. Therefore, clinicians encourage using digital therapeutics as it generates additional insights, resulting in a comprehensive patient health condition.
The Rising Prevalence of Chronic Diseases is Driving the Market Growth
The prevalence of chronic diseases and conditions such as diabetes, arthritis, and heart disease is rising globally. According to the WHO, in 2020, the prevalence of chronic diseases globally was estimated at 57%. Each year 41 million people succumb to chronic diseases, accounting for 71% of all deaths globally. Growth in the aging population and changes in social behaviors are major factors driving a steady increase in the number of people suffering from chronic diseases. For example, according to the International Diabetes Federation, in 2019, it was estimated that 19.3% of people aged 65 years and above had diabetes. In North America & the Caribbean, the prevalence of diabetes in people aged 65 years and above increased to 27.0% in 2019 from 26.3% in 2017 and is estimated to be 27.3% in 2030. In Europe, the diabetes prevalence in people aged 65 years and above increased to 24.2% in 2019 from 20.4% in 2017 and is estimated to increase to 24.7% in 2030. Thus, the growing prevalence of chronic diseases is driving the adoption of digital therapeutics solutions for regular health monitoring and treatment.
According to the World Population Ageing 2019 Report released by the Department of Economic and Social Affairs, United Nations, globally, the number of people aged 65 or above is estimated to reach 1.5 billion in 2050 from 703 million in 2019. In 2020, the geriatric population accounted for 9.3% of the global population. Similarly, according to United Nations, developing regions such as Asia, Latin America, and Africa have the highest proportions of the population aged 65 years and above, followed by Europe and North America. The geriatric population is prone to several chronic diseases. Therefore, the growing geriatric population, coupled with the rising burden of chronic diseases, is driving the growth of the digital therapeutics market.
Click here to: Get Free Sample Copy of this report
Untapped Markets in Emerging Economies are an Opportunity For the Global Digital Therapeutics Market
Emerging economies worldwide are fueling the demand for healthcare services and treatments due to rapid urbanization, improving healthcare infrastructure, increasing healthcare expenditures, increasing healthcare insurance coverage, rising disposable incomes, and the growing prevalence of non-communicable and infectious diseases.
According to the World Bank, the total population of emerging countries is projected to reach around 3.4 billion by 2050. Additionally, according to a report published in 2019 by Abbott Laboratories on diabetes, the total number of people with type 2 diabetes in emerging economies, mainly South Africa, India, Malaysia, Brazil, China, Thailand, and South Korea, was estimated at around 139 million. This number is estimated to increase by 79.1%, reaching 249 million by 2045. These factors are expected to boost the demand for digital therapeutics.
Growing urbanization and rising GDP per capita in emerging economies such as South Africa, India, Brazil, China, Bangladesh, and Thailand drive the demand for healthcare services and treatments. Growing urbanization indicates higher wages, a better quality of life, and improved access to healthcare services. Therefore, growing urbanization in emerging economies is expected to drive the development of healthcare systems, increasing people’s access to healthcare services, which, in turn, further leads to the proliferation of digital therapeutics in urban regions.
Thus, considering the overall scenario, factors such as the rising number of people suffering from chronic and infectious diseases, population growth, and increasing urbanization are expected to drive the demand for digital therapeutics solutions in emerging countries, creating significant growth opportunities for the companies operating in this market.
Based on component, in 2023, the software segment is expected to account for the largest share of this market
Based on component, the digital therapeutics market is segmented into software and devices. In 2023, the software segment is expected to account for the largest share of the digital therapeutics market. The large market share of this segment is attributed to the growing penetration of smartphone devices in developed and emerging nations, people’s inclination toward preventive health, and the high adoption of mHealth platforms.
Based on application, in 2023, the care-related segment is expected to account for the largest share of this market
Based on application, the digital therapeutics market is segmented into care-related applications and preventive applications. The care-related applications segment is further segmented into diabetes, central nervous system disorders, respiratory diseases, gastrointestinal disorders, smoking cessation, cardiovascular disorders, medication adherence, addiction management, rehabilitation and patient care, and other care-related applications. The preventive applications segment is further segmented into obesity, prediabetes, nutrition, and others. In 2023, the care-related applications segment is expected to account for the largest share of the digital therapeutics market. The large market share of this segment is attributed to the increased prevalence of chronic diseases, availability of cost-effective digital therapeutics solutions, increased investments in digital therapeutics, and the need to lower healthcare costs due to the rising economic burden of healthcare costs.
Based on end user, in 2023, the patients & caregivers segment is expected to account for the largest share of this market
The key factors contributing to the large market share of this segment are the high adoption of chronic diseases among patients, the trend of preventive healthcare, and increased awareness of the self-monitoring of diseases among patients and caregivers.
North America: Largest regional market
The large share of North America in the global digital therapeutics market is attributed to factors such as the increased prevalence of chronic diseases, surge in usage of digital health products, and rise in awareness among government agencies. Additionally, the number of players operating in the U.S. digital therapeutics market is high. North America has multiple digital therapeutic companies, including 2Morrow Inc. (U.S.), Welldoc, Inc. (U.S.), BigHealth (U.S.), Teladoc Health, Inc. (U.S.), and Pear Therapeutics (US), Inc. (U.S.). Additionally, the U.S. government supported digital therapeutics during the COVID-19 pandemic. For example, in April 2020, US Food and Drug Administration (FDA) eased certain premarket requirements for smartphone apps and programs specifically designed to support the treatment of conditions such as anxiety, obsessive-compulsive disorder, insomnia, and depression. These factors have contributed significantly to the large market share of this region in the global digital therapeutics market.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past years three years. The key players profiled in the global digital therapeutics market report are Noom, Inc. (U.S.), 2Morrow Inc. (U.S.), GAIA AG (Germany), Propeller Health (U.S.), CANARY HEALTH (U.S.), Welldoc, Inc. (U.S.), DarioHealth Corp. (U.S.), Akili, Inc. (U.S.), Pear Therapeutics (US), Inc. (U.S.), BigHealth (U.S.), Teladoc Health, Inc. (U.S.), Limbix Health, Inc. (U.S.), Kaia Health (Germany), Better Therapeutics, Inc (U.S.), and Fitbit LLC (U.S.).
Digital Therapeutics Market, by Component
Digital Therapeutics Market, by Application
Digital Therapeutics Market, by End User
Digital Therapeutics Market, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the digital therapeutics market, including the market size & forecast for various segmentations like component, application, and end user. The digital therapeutics market studied in this report also involves the value analysis of various segments and sub-segments of digital therapeutics at regional and country levels.
The global digital therapeutics market is projected to reach $22.16 billion by 2030, at a CAGR of 20.3% during the forecast period.
Based on component, in 2023, the software segment is expected to account for the largest share of this market. High penetration of digital healthcare and high adoption of mhealth platforms are the factors supporting the large market share of this segment.
Based on application, in 2023, the care-related segment is expected to account for the largest share of this market. The key factors supporting this segment's large market share are the availability of cost-effective digital therapeutics solutions, increased investments in digital therapeutics for care management, and a need to lower healthcare costs.
The growth of this market is mainly attributed to the increased need for reducing healthcare costs, the rise in the prevalence of chronic diseases, the high adoption of digital healthcare, and the increasing focus on preventive healthcare. Moreover, untapped markets in emerging economies and expanding pipelines for digital therapeutic solutions for various therapy areas offer significant opportunities for market growth.
The key players profiled in the global digital therapeutics market are Noom, Inc. (U.S.), 2Morrow Inc. (U.S.), GAIA AG (Germany), Propeller Health (U.S.), Canary Health (U.S.), Welldoc, Inc. (U.S.), DarioHealth Corp. (U.S.), Akili, Inc. (U.S.), Pear Therapeutics (US), Inc. (U.S.), BigHealth (U.S.), Teladoc Health, Inc. (U.S.), Limbix Health, Inc. (U.S.), Kaia Health Software Inc. (Germany), Better Therapeutics, Inc (U.S.), and Fitbit LLC (U.S.).
In 2023, North America is expected to account for the largest share of the global digital therapeutics market. Increased usage of digital health products, rise in government initiatives to support technological advancements, and surge in the prevalence of chronic diseases are the factors contributing to the large market share of this region.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for this Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Rising Prevalence of Chronic Diseases
4.2.2. Increasing Focus on Preventive Healthcare
4.2.3. Concern Over Healthcare Expenditure
4.2.4. Increasing Awareness of Digital Therapeutics
4.3. Restraints
4.3.1. Data Privacy Concerns
4.4. Opportunities
4.4.1. Untapped Markets in Emerging Economies
4.4.2. Large Customer Pool
4.5. Challenges
4.5.1. Hesitation Over the Adoption of Digital therapeutics
4.5.2. Reluctance From Traditional Healthcare Providers
4.6. Impact of the COVID-19 Pandemic on the Digital Therapeutics Market
5. Digital Therapeutics Market, by Component
5.1. Introduction
5.2. Software
5.3. Device
6. Digital Therapeutics Market, by Application
6.1. Introduction
6.2. Care-related Applications
6.2.1. Diabetes
6.2.2. CNS Disorders
6.2.3. Respiratory Disorders
6.2.4. Gastrointestinal Disorders
6.2.5. Smoking Cessation
6.2.6. Cardiovascular Diseases
6.2.7. Medication Adherence
6.2.8. Addiction management
6.2.9. Rehabilitation and patient care
6.2.10. Other Care-Related Applications
6.3. Preventive Applications
6.3.1. Obesity
6.3.2. Prediabetes
6.3.3. Nutrition
6.3.4. Other Preventive Applications
7. Digital Therapeutics Market, by End User
7.1. Introduction
7.2. Payers
7.3. Patients & Caregivers
7.4. Providers
7.5. Employers
8. Digital Therapeutics Market, by Geography
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America
8.6. Middle East & Africa
9. Competitive Landscape
9.1. Introduction
9.2. Key Growth Strategies
9.3. Market Share Analysis (2022)
10. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)
10.1. Noom, Inc.
10.2. 2Morrow Inc.
10.3. GAIA AG
10.4. Propeller Health
10.5. Canary Health
10.6. Welldoc, Inc.
10.7. DarioHealth Corp.
10.8. Akili, Inc.
10.9. Pear Therapeutics (US), Inc.
10.10. BigHealth
10.11. Teladoc Health, Inc.
10.12. Limbix Health, Inc.
10.13. Kaia Health Software Inc.
10.14. Better Therapeutics, Inc
10.15. Fitbit LLC
11. Appendix
11.1. Questionnaire
11.2. Available Customization
List of Tables
Table 1 Global Digital Therapeutics Drivers: Impact Analysis (2023–2030)
Table 2 Global Digital Therapeutics Restraints: Impact Analysis (2023–2030)
Table 3 Global Digital Therapeutics Size, by Component, 2021–2030 (USD Million)
Table 4 Global Digital Therapeutics Market Size for Software, by Country/Region, 2021–2030 (USD Million)
Table 5 Global Digital Therapeutics Market Size for Device, by Country/Region, 2021–2030 (USD Million)
Table 6 Global Digital Therapeutics Size, by Application, 2021–2030 (USD Million)
Table 7 Global Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 8 Global Care-related Digital Therapeutics Market Size, by Country/Region, 2021–2030 (USD Million)
Table 9 Global Care-related Digital Therapeutics Market Size for Diabetes, by Country/Region, 2021–2030 (USD Million)
Table 10 Global Care-related Digital Therapeutics Market Size for CNS Disorders, by Country/Region, 2021–2030 (USD Million)
Table 11 Global Care-related Digital Therapeutics Market Size for Respiratory Disorders, by Country/Region, 2021–2030 (USD Million)
Table 12 Global Care-related Digital Therapeutics Market Size for Gastro-intestinal Disorders, by Country/Region, 2021–2030 (USD Million)
Table 13 Global Care-related Digital Therapeutics Market Size for Smoking Cessation, by Country/Region, 2021–2030 (USD Million)
Table 14 Global Care-related Digital Therapeutics Market Size for Cardiovascular Diseases, by Country/Region, 2021–2030 (USD Million)
Table 15 Global Care-related Digital Therapeutics Market Size for Medication Adherence, by Country/Region, 2021–2030 (USD Million)
Table 16 Global Care-related Digital Therapeutics Market Size for Addiction management, by Country/Region, 2021–2030 (USD Million)
Table 17 Global Care-related Digital Therapeutics Market Size for Rehabilitation and patient care, by Country/Region, 2021–2030 (USD Million)
Table 18 Global Other Care-related Digital Therapeutics Market Size, by Country/Region, 2021–2030 (USD Million)
Table 19 Global Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 20 Global Preventive Digital Therapeutics Market Size for Obesity, by Country/Region, 2021–2030 (USD Million)
Table 21 Global Preventive Digital Therapeutics Market Size for Prediabetes, by Country/Region, 2021–2030 (USD Million)
Table 22 Global Preventive Digital Therapeutics Market Size for Nutrition, by Country/Region, 2021–2030 (USD Million)
Table 23 Global Preventive Digital Therapeutics Market Size for Other Preventive Applications, by Country/Region, 2021–2030 (USD Million)
Table 24 Global Preventive Digital Therapeutics Size, by End User, 2021–2030 (USD Million)
Table 25 Global Preventive Digital Therapeutics Market Size for Patients and Caregivers, 2021–2030 (USD Million)
Table 26 Global Preventive Digital Therapeutics Market Size for Payers, by Country/Region, 2021–2030 (USD Million)
Table 27 Global Preventive Digital Therapeutics Market Size for Employers, by Country/Region, 2021–2030 (USD Million)
Table 28 Global Preventive Digital Therapeutics Market Size for Providers, by Country/Region, 2021–2030 (USD Million)
Table 29 Global Digital Therapeutics Market Size, by Country/Region, 2021–2030 (USD Million)
Table 30 North America: Digital Therapeutics Market Size, by Country, 2021–2030 (USD Million)
Table 31 North America: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 32 North America: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 33 North America: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 34 North America: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 35 North America: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 36 U.S.: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 37 U.S.: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 38 U.S.: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 39 U.S.: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 40 U.S.: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 41 Canada: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 42 Canada: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 43 Canada: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 44 Canada: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 45 Canada: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 46 Europe: Digital Therapeutics Market Size, by Country/Region, 2021–2030 (USD Million)
Table 47 Europe: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 48 Europe: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 49 Europe: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 50 Europe: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 51 Europe: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 52 Germany: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 53 Germany: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 54 Germany: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 55 Germany: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 56 Germany: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 57 France: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 58 France: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 59 France: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 60 France: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 61 France: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 62 U.K.: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 63 U.K.: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 64 U.K.: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 65 U.K.: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 66 U.K.: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 67 Italy: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 68 Italy: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 69 Italy: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 70 Italy: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 71 Italy: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 72 Spain: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 73 Spain: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 74 Spain: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 75 Spain: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 76 Spain: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 77 Rest of Europe: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 78 Rest of Europe: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 79 Rest of Europe: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 80 Rest of Europe: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 81 Rest of Europe: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 82 Asia-Pacific: Digital Therapeutics Market Size, by Country/Region, 2021–2030 (USD Million)
Table 83 Asia-Pacific: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 84 Asia-Pacific: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 85 Asia-Pacific: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 86 Asia-Pacific: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 87 Asia-Pacific: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 88 China: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 89 China: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 90 China: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 91 China: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 92 China: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 93 Japan: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 94 Japan: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 95 Japan: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 96 Japan: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 97 Japan: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 98 India: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 99 India: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 100 India: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 101 India: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 102 India: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 103 Rest of Asia-Pacific: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 104 Rest of Asia-Pacific: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 105 Rest of Asia-Pacific: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 106 Rest of Asia-Pacific: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 107 Rest of Asia-Pacific: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 108 Latin America: Digital Therapeutics Market Size, by Country/Region, 2021–2030 (USD Million)
Table 109 Latin America: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 110 Latin America: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 111 Latin America: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 112 Latin America: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 113 Latin America: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 114 Brazil: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 115 Brazil: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 116 Brazil: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 117 Brazil: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 118 Brazil: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 119 Mexico: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 120 Mexico: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 121 Mexico: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 122 Mexico: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 123 Mexico: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 124 Rest of Latin America: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 125 Rest of Latin America: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 126 Rest of Latin America: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 127 Rest of Latin America: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 128 Rest of Latin America: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 129 Middle East & Africa: Digital Therapeutics Market Size, by Component, 2021–2030 (USD Million)
Table 130 Middle East & Africa: Digital Therapeutics Market Size, by Application, 2021–2030 (USD Million)
Table 131 Middle East & Africa: Care-related Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 132 Middle East & Africa: Preventive Digital Therapeutics Size, by Type, 2021–2030 (USD Million)
Table 133 Middle East & Africa: Digital Therapeutics Market Size, by End User, 2021–2030 (USD Million)
Table 134 Recent Developments, by Company, 2019–2022
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 Global Digital Therapeutics Size, by Component, 2023 Vs. 2030 (USD Million)
Figure 8 Global Digital Therapeutics Size, by Application, 2023 Vs. 2030 (USD Million)
Figure 9 Global Digital Therapeutics Size, by End User, 2023 Vs. 2030 (USD Million)
Figure 10 Digital Therapeutics Market, by Region
Figure 11 Market Dynamics
Figure 12 Global Digital Therapeutics Size, by Component, 2023 Vs. 2030 (USD Million)
Figure 13 Global Digital Therapeutics Size, by Application, 2023 Vs. 2030 (USD Million)
Figure 14 Global Digital Therapeutics Size, by End User, 2023 Vs. 2030 (USD Million)
Figure 15 Global Digital Therapeutics Size, by Region, 2023 Vs. 2030 (USD Million)
Figure 16 North America: Digital Therapeutics Snapshot
Figure 17 Europe: Digital Therapeutics Snapshot
Figure 18 Asia-Pacific: Digital Therapeutics Snapshot
Figure 19 Market Share Analysis: Digital Therapeutics Market, 2021
Figure 20 DarioHealth Corp.: Financial Overview, 2021
Figure 21 Akili, Inc.: Financial Overview, 2021
Figure 22 Pear Therapeutics (US), Inc.: Financial Overview, 2021
Figure 23 Teladoc Health, Inc.: Financial Overview, 2021
Figure 24 Better Therapeutics, Inc: Financial Overview, 2021
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Apr-2023
Published Date: Mar-2023
Published Date: Jan-2023
Published Date: Nov-2022
